Third-line sorafenib after sequential therapy with sunitinib and mtor inhibitors in metastatic renal cell carcinoma

European Urology

Volumn 58, Issue 6, 2010, Pages 906-911

  Di Lorenzo, Giuseppe ^a   Buonerba, Carlo ^a   Federico, Piera ^a   Rescigno, Pasquale ^a   Milella, Michele ^b   Ortega, Cinzia ^c   Aieta, Michele ^d   D'Aniello, Carmine ^a   Longo, Nicola ^a   Felici, Alessandra ^b   Ruggeri, Enzo Maria ^b   Palmieri, Giovannella ^a   Imbimbo, Ciro ^a   Aglietta, Massimo ^c   De Placido, Sabino ^a   Mirone, Vincenzo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c CANDIOLO CANCER INSTITUTE   (Italy)

^d Ospedale Oncologico Regionale   (Italy)

Author keywords

Metastatic renal cell cancer; Sequential therapy; Sorafenib

Indexed keywords

EVEROLIMUS; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADULT; AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; HUMANS; INDOLES; ITALY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; RETROSPECTIVE STUDIES; SIROLIMUS; SURVIVAL RATE; TIME FACTORS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 78049463142     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.09.008     Document Type: Article

References (14)

1. G. Di Lorenzo, R. Autorino, and C.N. Sternberg Metastatic renal cell carcinoma: recent advances in the targeted therapy era Eur Urol 56 2009 959 971
2. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
3. B.B. McGuire, and J.M. Fitzpatrick Biomarkers in renal cell carcinoma Curr Opin Urol 19 2009 441 446
4. G. Di Lorenzo, G. Carten, and R. Autorino Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer J Clin Oncol 27 2009 4469 4474
5. R. Casciano, E. Malangone, and S. Sherman An indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory mRCC patients J Clin Oncol 28 2010 15s
6. B.I. Rini New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance Clin Cancer Res 16 2010 1348 1354
7. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
8. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
9. E.J. Mills, B. Rachlis, C. O'Regan, L. Thabane, and D. Perri Metastatic renal cell cancer treatments: an indirect comparison meta-analysis BMC Cancer 9 2009 34
10. J.S. Thompson Coon, Z. Liu, and M. Hoyle Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness Br J Cancer 101 2009 238 243
11. R.J. Motzer, B. Escudier, and S. Oudard Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
12. Mackenzie MJ, Rini BI, Elson P, et al. Temsirolimus in VEGF-refractory metastatic renal cell carcinoma. Ann Oncol. In press.
13. Rini BI, Hutson TE, Elson P, et al. Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma. Abstract presented at: American Society Clinical Oncology (ASCO), Genitourinary Cancers Symposium; March 2010; San Francisco, CA, USA. Abstract 319.
14. Gruenwald V, Seidel C, Fenner M, et al. Antitumor activity of tyrosine kinase inhibitors (TKI) after failure of RAD001 in metastatic renal cell carcinoma (mRCC). Abstract presented at: American Society Clinical Oncology (ASCO), Genitourinary Cancers Symposium; March 2010; San Francisco, CA, USA. Abstract 414.